PMID- 24011786
OWN - NLM
STAT- MEDLINE
DCOM- 20140127
LR  - 20211203
IS  - 1532-1967 (Electronic)
IS  - 0305-7372 (Linking)
VI  - 40
IP  - 2
DP  - 2014 Mar
TI  - Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer.
PG  - 320-6
LID - S0305-7372(13)00169-2 [pii]
LID - 10.1016/j.ctrv.2013.08.004 [doi]
AB  - The mammalian target of rapamycin (mTOR) inhibitor class of drugs represents the 
      newest addition to the armamentarium of therapies for hormonally driven breast 
      cancer. It has recently been shown that the addition of mTOR inhibitor everolimus 
      to aromatase inhibitors in hormone receptor-positive breast cancers improves 
      progression-free survival. However, a clinically significant toxicity associated 
      with this class of drugs is the development of noninfectious pneumonitis (NIP). 
      Although generally mild and manageable, everolimus-induced NIP requires prompt 
      diagnosis and management. This article will provide a brief overview of data 
      relating to dysregulation of the phosphatidylinositol-3-kinase/protein kinase 
      B/mTOR pathway in breast cancer; review the literature relating to the efficacy 
      and safety of mTOR inhibitors in breast cancer; and evaluate the incidence, 
      severity, and optimal management of mTOR inhibitor-related NIP in breast cancer.
CI  - Published by Elsevier Ltd.
FAU - Peddi, Parvin F
AU  - Peddi PF
AD  - Department of Medicine, Division of Hematology-Oncology, University of 
      California, Los Angeles, CA 90404, USA. Electronic address: 
      ppeddi@mednet.ucla.edu.
FAU - Shatsky, Rebecca A
AU  - Shatsky RA
FAU - Hurvitz, Sara A
AU  - Hurvitz SA
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20130814
PL  - Netherlands
TA  - Cancer Treat Rev
JT  - Cancer treatment reviews
JID - 7502030
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Elafin)
RN  - 0 (PI3 protein, human)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Antineoplastic Agents/*administration & dosage/*adverse effects
MH  - Breast Neoplasms/*drug therapy/metabolism
MH  - Cough/chemically induced
MH  - Dyspnea/chemically induced
MH  - Elafin/antagonists & inhibitors
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Incidence
MH  - Pneumonia/*chemically induced/diagnosis
MH  - Proto-Oncogene Proteins c-akt/antagonists & inhibitors
MH  - Severity of Illness Index
MH  - Signal Transduction/drug effects
MH  - Sirolimus/administration & dosage/adverse effects/*analogs & derivatives
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
OTO - NOTNLM
OT  - Breast cancer
OT  - Cough
OT  - Dyspnea
OT  - Everolimus
OT  - Noninfectious pneumonitis
OT  - mTOR inhibitors
EDAT- 2013/09/10 06:00
MHDA- 2014/01/28 06:00
CRDT- 2013/09/10 06:00
PHST- 2013/04/29 00:00 [received]
PHST- 2013/08/02 00:00 [revised]
PHST- 2013/08/06 00:00 [accepted]
PHST- 2013/09/10 06:00 [entrez]
PHST- 2013/09/10 06:00 [pubmed]
PHST- 2014/01/28 06:00 [medline]
AID - S0305-7372(13)00169-2 [pii]
AID - 10.1016/j.ctrv.2013.08.004 [doi]
PST - ppublish
SO  - Cancer Treat Rev. 2014 Mar;40(2):320-6. doi: 10.1016/j.ctrv.2013.08.004. Epub 
      2013 Aug 14.